Portage Biotech Inc. (NASDAQ:PRTG) shares are up Monday after the company reported updated interim data from the Phase 1 portion of the trial evaluating its lead invariant natural killer T cell (iNKT) engager, PORT-2 (IMM60) at the 2023 ASCO Annual Meeting.

What To Know:  The interim data showed early evidence of single agent activity with viable reduction of several target lesions. 

"We're pleased to report early evidence of single agent activity for PORT-2, with interim tumor assessment data showing several target lesions were substantially reduced in size or completely resolved, and a majority of target lesions being clinically stable after twelve weeks," said Dr. Ian Walters, Chief Executive Officer and Chairman of Portage Biotech.

Portage plans to expand the Phase 1 portion of the trail after encouraging safety and tolerability data for PORT-2. Data is expected by the end of 2023.

Related Link: Replimune Group shares are trading higher on continued upward momentum after the company presented data from the IGNYTE anti-PD1 failed melanoma cohort and Phase 1 trial of RP2 data in patients with uveal melanoma at the 2023 ASCO annual meeting.

PRTG Price Action: Shares of PRTG were up 3.97% at $3.80 at the time of publication, according to Benzinga Pro.

Image by Ewa Urban from Pixabay